Jeffrey M. Leiden - Nov 13, 2025 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Nov 13, 2025
Transactions value $
-$25,799,237
Form type
4
Date filed
11/17/2025, 04:12 PM
Previous filing
Feb 19, 2025
Next filing
Dec 5, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
LEIDEN JEFFREY M Executive Chairman, Director C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON /s/ Christiana Stevenson, Attorney-in-Fact 2025-11-17 0001242825

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Options Exercise $1.79M +19.7K +81.94% $91.05 43.7K Nov 13, 2025 Direct
transaction VRTX Common Stock Sale -$8.16M -18.5K -42.38% $440.22 25.2K Nov 13, 2025 Direct F1, F2, F3
transaction VRTX Common Stock Sale -$512K -1.16K -4.61% $441.05 24K Nov 13, 2025 Direct F1, F2, F4
transaction VRTX Common Stock Options Exercise $1.26M +13.8K +57.58% $91.05 37.9K Nov 14, 2025 Direct
transaction VRTX Common Stock Options Exercise $3.44M +39.8K +105.04% $86.52 77.6K Nov 14, 2025 Direct
transaction VRTX Common Stock Sale -$14.2M -32.2K -41.52% $440.30 45.4K Nov 14, 2025 Direct F1, F2, F5
transaction VRTX Common Stock Sale -$9.41M -21.3K -46.99% $441.35 24.1K Nov 14, 2025 Direct F1, F2, F6
transaction VRTX Common Stock Sale -$17.7K -40 -0.17% $442.00 24K Nov 14, 2025 Direct F1
holding VRTX Common Stock 440 Nov 13, 2025 401(k)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRTX Stock Option (Right to Buy) Options Exercise $0 -19.7K -58.73% $0.00 13.8K Nov 13, 2025 Common Stock 19.7K $91.05 Direct F7
transaction VRTX Stock Option (Right to Buy) Options Exercise $0 -13.8K -99.99% $0.00 1 Nov 14, 2025 Common Stock 13.8K $91.05 Direct F7
transaction VRTX Stock Option (Right to Buy) Options Exercise $0 -39.8K -38.41% $0.00 63.8K Nov 14, 2025 Common Stock 39.8K $86.52 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025.
F2 Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $440.22 (range $440.00 to $440.99).
F4 Open market sales reported on this line occurred at a weighted average price of $441.05 (range $441.00 to $441.10).
F5 Open market sales reported on this line occurred at a weighted average price of $440.30 (range $440.00 to $440.99).
F6 Open market sales reported on this line occurred at a weighted average price of $441.35 (range $441.00 to $441.99).
F7 Fully vested.